BIOMAT Database Logo BIOMAT Database Logo

Antihypertensive effect of beta-1 receptor blockade and beta-2-receptor stimulation in essential hypertension. 1975

O Andersson, and G Berglund

The antihypertensive effect of practolol, a beta-1-blocker, alone and in combination with a beta-2-stimulating drug, salbutamol, has been studied in a double-blind cross-over trial on 19 patients. Practolol treatment induced a significant BP reduction, while the addition of salbutamol failed to give any further decrease.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011217 Practolol A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS. Dalzic,Eralzdin Practolol,ICI-50172,ICI 50172,ICI50172,Practolol, Eralzdin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

O Andersson, and G Berglund
Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension.
March 1978, The American journal of medicine,
O Andersson, and G Berglund
[Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension: the effect of atenolol (author's transl)].
April 1977, Deutsche medizinische Wochenschrift (1946),
O Andersson, and G Berglund
Combined beta 1-adrenoceptor blockade and/or beta 2- or beta 1/2 adrenoceptor stimulation as treatment of essential hypertension.
December 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
O Andersson, and G Berglund
Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension.
August 1987, Hypertension (Dallas, Tex. : 1979),
O Andersson, and G Berglund
Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.
May 1993, Clinical and experimental hypertension (New York, N.Y. : 1993),
O Andersson, and G Berglund
Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients.
December 1990, Clinical pharmacology and therapeutics,
O Andersson, and G Berglund
[Effect of chronic beta-receptor blockade in blood pressure and renin and aldosterone secretion in essential hypertension].
January 1975, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
O Andersson, and G Berglund
AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats.
November 1999, Hypertension (Dallas, Tex. : 1979),
O Andersson, and G Berglund
Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
September 1989, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,
O Andersson, and G Berglund
[Essential arterial hypertension. Antihypertensive effect of the beta adrenergic blockader pindolol].
January 1977, La Prensa medica mexicana,
Copied contents to your clipboard!